India Streamlines Regulations for Clinical Research

With the aim of creating a conducive environment that fosters research and new drug development in India, the government has amended some critical clauses and framed new guidelines that are aligned to global regulations.
In an interview with BioSpectrum Asia Magazine, Suneela Thatte, president, Indian Society for Clinical Research said that India now has a very robust regulatory environment which is focused on quality, and where patient safety and confidentiality is not compromised.
“The compensation guidelines for clinical research are now more balanced and rational, and formulae have been introduced by the regulators for calculating the financial compensation based on a no-fault principle. This not only provides ease of implementation and consistency but also helps the sponsor of the trial to understand the maximum possible liability and plan appropriately while protecting the patient well being,” she said.
Clinical Trials

Restrictions on the number of clinical trials an investigator could do at a given point in time, and the minimum number of beds a clinical trial site needed to have, have been removed.Thatte added, “We hope the new regulatory environment will encourage more innovative and path-breaking R&D in our local biopharma companies as also in many of our well established teaching and academic institutions.

Be Sociable, Share!
Posted on by Gunjan Bagla
Gunjan Bagla
California-based management consultant Gunjan Bagla runs Amritt, a consulting firm helping American companies to succeed in India. Amritt is the trusted advisor for India market research, India business development, India market entry, Global Engineering, Global Technology Scouting, India R&D and Open Innovation. Gunjan is author of "Business in 21st Century India: How to Profit Today from Tomorrow’s Most Exciting Market" (Hachette Book Group, 2008), Amazon's top rated title on the subject. He has appeared as the India Expert on BBC Television, Bloomberg TV, Fox Cable Business and has been quoted in the New York Times, the Los Angeles Times, the Hollywood Reporter and Business Week for his expertise on India.

0 comments

There are no comments yet...

Kick things off by filling out the form below.

Leave a Comment

*